Sunesis Announces Publication of Phase 1b Data of Vosaroxin in Relapsed or Refractory Acute Leukemia

Sunesis Pharmaceuticals, Inc. SNSS today announced the publication in Leukemia of data from a Phase 1b multi-center study of vosaroxin in relapsed or refractory leukemia. The results show that single-agent vosaroxin was well-tolerated, with a potent anti-leukemic effect in patients who had received multiple prior therapies. The Phase 1b data, along with results from Phase 2 studies of vosaroxin used alone and in combination with cytarabine in the treatment of acute myeloid leukemia, support the Company's currently-enrolling VALOR trial, a Phase 3, multinational, randomized, double-blind, placebo-controlled, pivotal clinical trial of vosaroxin in combination with cytarabine in first relapsed or refractory AML.